Rabeprazole Sodium Market

Global Rabeprazole Sodium Market Size, Share & Trends Analysis Report By Age, By Distribution Channel (Drug & Retail Store Pharmacies, Hospital Pharmacies and Online Pharmacies), By Application, By Regional Outlook and Forecast, 2024 - 2031

Report Id: KBV-23487 Publication Date: July-2024 Number of Pages: 219
2023
USD 638.3 Million
2031
USD 845.3 Million
CAGR
3.7%
Historical Data
2020 to 2022

Market Report Description

The Global Rabeprazole Sodium Market size is expected to reach $845.3 million by 2031, rising at a market growth of 3.7% CAGR during the forecast period.

Several factors contribute to this dominance, such as the high incidence of peptic ulcers and gastroesophageal reflux disease (GERD) in the general population. Additionally, the region boasts a well-established healthcare infrastructure, extensive insurance coverage, and high healthcare spending, facilitating access to advanced gastrointestinal treatments. The market growth of North America is further supported by the presence of prominent pharmaceutical companies and ongoing research and development initiatives. Thus, the North America region acquired 40.5% revenue share in the market 2023.

Rabeprazole Sodium Market Size - Global Opportunities and Trends Analysis Report 2020-2031

GERD is one of the most common gastrointestinal disorders. It is distinguished by the reflux of gastric acid into the esophagus, which results in symptoms such as regurgitation, chest pain, and heartburn. According to the National Library of Medicine, GERD impacts up to 20% of the adult population in Western countries.

Additionally, Innovations in pharmaceutical formulations and drug delivery systems have significantly enhanced rabeprazole sodium's efficacy and patient compliance, positioning it as a cornerstone in treating gastrointestinal disorders. Therefore, the continuous innovation in pharmaceutical formulations and drug delivery systems has transformed the market landscape.

However, several studies have indicated that prolonged suppression of stomach acid can interfere with calcium absorption, which is critical for bone health. This reduction in calcium absorption may lead to a density of bone minerals that is less than normal, which in turn elevates the risk of fractures, notably in the wrist, spine, and hip. Hence, all these concerns may impede the adoption of it.

Adapting healthcare delivery models to accommodate pandemic-related challenges fostered innovation in telehealth services and remote patient monitoring. Telemedicine emerged as a viable option for managing chronic gastrointestinal conditions, ensuring continuity of care while minimizing exposure risks during periods of lockdowns and social distancing measures. Hence, the pandemic had an overall negative impact on the market.

Driving and Restraining Factors
Rabeprazole Sodium Market
  • Rising prevalence of gastrointestinal disorders
  • Growing geriatric population across the world
  • Advancements in pharmaceutical formulations
  • Adverse effects and safety concerns
  • Availability of alternative therapies
  • Increasing awareness and diagnosis
  • Favorable reimbursement policies and insurance coverage
  • Stringent regulatory requirements
  • Inadequate or inconsistent reimbursement policies

Age Outlook

On the basis of age, the market is classified into below 55 years and above 55 years. The below 55 years segment acquired 67.9% revenue share in the market in 2023. This demographic includes younger adults and middle-aged individuals who are increasingly affected by gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders.

Distribution Channel Outlook

By distribution channel, the market is divided into hospital pharmacies, drug & retail store pharmacies, and online providers. The hospital pharmacies segment garnered 24% revenue share in the market in 2023. Hospital pharmacies are integral to healthcare settings, catering to inpatients and outpatients with specialized pharmaceutical needs.

Rabeprazole Sodium Market Share and Industry Analysis Report 2023

Application Outlook

Based on application, the market is characterized into gastroesophageal reflux disease, peptic ulcer, and others. The gastroesophageal reflux disease segment garnered 58.3% revenue share in the market in 2023. Chest pain, regurgitation, and heartburn are some of the symptoms associated with GERD, which is a chronic digestive ailment that is characterized by the reflux of gastric acid into the esophagus.

Free Valuable Insights: Global Rabeprazole Sodium Market size to reach USD 845.3 Million by 2031

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 25.5% revenue share in the market in 2023. This region encompasses rapidly growing economies such as China, India, and Japan, where gastrointestinal disorders are increasing due to urbanization, changing dietary habits, and lifestyle modifications.

Rabeprazole Sodium Market Report Coverage
Report AttributeDetails
Market size value in 2023USD 638.3 Million
Market size forecast in 2031USD 845.3 Million
Base Year2023
Historical Period2020 to 2022
Forecast Period2024 to 2031
Revenue Growth RateCAGR of 3.7% from 2024 to 2031
Number of Pages219
Number of Tables340
Report coverageMarket Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments coveredAge, Distribution Channel, Application, Region
Country scope
  • North America (US, Canada, Mexico, and Rest of North America)
  • Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific)
  • LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies IncludedCipla Limited, Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Woodward Pharma, Elikem Pharmaceuticals Pvt Ltd., Jasco Labs Private Limited and Torrent Pharmaceuticals Ltd.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Reddy’s Laboratories Ltd.
  • Cadila Pharmaceuticals Ltd
  • Alembic Pharmaceuticals Ltd
  • Woodward Pharma
  • Elikem Pharmaceuticals Pvt Ltd
  • Jasco Labs Private Limited
  • Torrent Pharmaceuticals Ltd.

Rabeprazole Sodium Market Report Segmentation

By Age

  • Below 55 years and
  • Above 55 years

By Distribution Channel

  • Drug & Retail Store Pharmacies,
  • Hospital Pharmacies and
  • Online Pharmacies

By Application

  • Gastroesophageal Reflux Disease,
  • Peptic Ulcer and
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo